The last time I wrote about Larimar Therapeutics, Inc. (NASDAQ:LRMR) it was in a Seeking Alpha article entitled "Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely ...
Larimar Reports Positive Initial Data From Long-term OLE Study Of Nomlabofusp In Friedreich's Ataxia
(RTTNews) - Larimar Therapeutics, Inc. (LRMR), Monday announced positive initial data from the long-term open label extension (OLE) study of nomlabofusp in participants with Friedreich's Ataxia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback